Penserra Capital Management LLC Takes Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Penserra Capital Management LLC acquired a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 47,855 shares of the biopharmaceutical company's stock, valued at approximately $1,886,000.

Several other hedge funds have also modified their holdings of the stock. Braun Stacey Associates Inc. raised its stake in shares of TG Therapeutics by 13.5% in the first quarter. Braun Stacey Associates Inc. now owns 502,650 shares of the biopharmaceutical company's stock valued at $19,819,000 after acquiring an additional 59,845 shares in the last quarter. Principal Financial Group Inc. raised its stake in TG Therapeutics by 1.3% in the first quarter. Principal Financial Group Inc. now owns 841,011 shares of the biopharmaceutical company's stock valued at $33,161,000 after buying an additional 10,827 shares in the last quarter. New York State Teachers Retirement System raised its stake in TG Therapeutics by 175.0% in the first quarter. New York State Teachers Retirement System now owns 120,364 shares of the biopharmaceutical company's stock valued at $4,746,000 after buying an additional 76,600 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in TG Therapeutics by 54.0% in the first quarter. Allspring Global Investments Holdings LLC now owns 23,775 shares of the biopharmaceutical company's stock valued at $898,000 after buying an additional 8,338 shares in the last quarter. Finally, Highland Capital Management LLC acquired a new stake in TG Therapeutics in the first quarter valued at $207,000. 58.58% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other TG Therapeutics news, Director Yann Echelard sold 10,000 shares of the firm's stock in a transaction dated Friday, June 13th. The stock was sold at an average price of $36.94, for a total transaction of $369,400.00. Following the transaction, the director owned 228,816 shares of the company's stock, valued at approximately $8,452,463.04. This trade represents a 4.19% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 10.64% of the company's stock.

TG Therapeutics Stock Down 2.0%

TG Therapeutics stock opened at $35.98 on Tuesday. TG Therapeutics, Inc. has a 1-year low of $16.65 and a 1-year high of $46.48. The company has a debt-to-equity ratio of 1.03, a current ratio of 4.02 and a quick ratio of 3.04. The stock has a market cap of $5.71 billion, a PE ratio of 149.92 and a beta of 1.91. The stock's fifty day moving average is $36.65 and its two-hundred day moving average is $35.19.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.19 by ($0.16). TG Therapeutics had a net margin of 10.13% and a return on equity of 18.88%. The business had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same quarter in the prior year, the business earned ($0.07) earnings per share. The firm's quarterly revenue was up 90.4% on a year-over-year basis. On average, sell-side analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

Want to see what other hedge funds are holding TGTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.